ROSEN TERRY J 4

What Happened

• Terry J. Rosen, Chief Executive Officer of Arcus Biosciences (RCUS), was granted a total of 394,000 shares on January 23, 2026. The Form 4 shows two award entries: 79,000 shares acquired at $0.00 and 315,000 derivative shares acquired at $0.00 (total consideration $0, typical for RSU awards). These are compensation awards (not open-market purchases or sales).

Key Details

• Transaction date: January 23, 2026. Filing date: January 26, 2026 (Form 4 accession 0001182473-26-000005).
• Price: $0.00 per share (award/grant).
• Share counts: 79,000 shares + 315,000 derivative RSUs = 394,000 total awards.
• Shares owned after transaction: Not specified in the provided summary; the filing notes holdings include unvested RSUs (see F2).
• Relevant footnotes:
  • F1: The RSUs vest in four equal annual installments beginning December 15, 2026, subject to continued service.
  • F2: Holdings reported include the unvested portion of RSU grants.
  • F3: Separately references an option that becomes exercisable in 48 equal monthly installments after January 1, 2026.
• Timeliness: Filed Jan 26 for a Jan 23 transaction — appears to be within the typical 2-business-day Form 4 deadline (i.e., not evidently late).

Context

• These entries are awards/compensation (RSUs and related derivative awards). RSUs typically convert to shares as they vest and do not represent an immediate cash purchase or sale; they signal company compensation decisions rather than direct insider buying or selling for market exposure.
• Footnote F3 points to an option vesting schedule (monthly over 48 months) referenced in the filing; this is informational about other incentive awards rather than an immediate exercise/sale.